Literature DB >> 30021770

Pre-Existing Maternal Antibodies Cause Rapid Prenatal Rejection of Allotransplants in the Mouse Model of In Utero Hematopoietic Cell Transplantation.

John S Riley1, Lauren E McClain1, John D Stratigis1, Barbara E Coons1, Haiying Li1, Heather A Hartman1, William H Peranteau2.   

Abstract

In utero hematopoietic cell transplantation (IUHCT) is a nonmyeloablative nonimmunosuppressive alternative to postnatal hematopoietic stem cell transplantation for the treatment of congenital hemoglobinopathies. Anti-HLA donor-specific Abs (DSA) are associated with a high incidence of graft rejection following postnatal hematopoietic stem cell transplantation. We determine if DSA present in the mother can similarly cause graft rejection in the fetus following IUHCT. Ten million C57BL/6 (B6, H2kb) bone marrow cells were transplanted in utero into gestational day 14 BALB/c (H2kd) fetuses. The pregnant BALB/c dams carrying these fetuses either had been previously sensitized to B6 Ag or were injected on gestational days 13-15 with serum from B6-sensitized BALB/c females. Maternal-fetal Ab transmission, Ab opsonization of donor cells, chimerism, and frequency of macrochimeric engraftment (chimerism >1%) were assessed by flow cytometry. Maternal IgG was transmitted to the fetus and rapidly opsonized donor cells following IUHCT. Donor cell rejection was observed as early as 4 h after IUHCT in B6-sensitized dams and 24 h after IUHCT in dams injected with B6-sensitized serum. Efficient opsonization was strongly correlated with decreased chimerism. No IUHCT recipients born to B6-sensitized dams or dams injected with B6-sensitized serum demonstrated macrochimeric engraftment at birth compared with 100% of IUHCT recipients born to naive dams or dams injected with naive serum (p < 0.001). In summary, maternal donor-specific IgG causes rapid, complete graft rejection in the fetus following IUHCT. When a third-party donor must be used for clinical IUHCT, the maternal serum should be screened for DSA to optimize the chance for successful engraftment.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30021770      PMCID: PMC6103848          DOI: 10.4049/jimmunol.1800183

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

Review 1.  In utero hematopoietic stem cell transplantation: ontogenic opportunities and biologic barriers.

Authors:  A W Flake; E D Zanjani
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

2.  Transplantation of human peripheral blood stem cells into fetal rhesus monkeys (Macaca mulatta).

Authors:  A F Tarantal; O Goldstein; F Barley; M J Cowan
Journal:  Transplantation       Date:  2000-05-15       Impact factor: 4.939

3.  The acquired immunity concept in kidney homotransplantation.

Authors:  M SIMONSEN
Journal:  Ann N Y Acad Sci       Date:  1955-01-24       Impact factor: 5.691

4.  Actively acquired tolerance of foreign cells.

Authors:  R E BILLINGHAM; L BRENT; P B MEDAWAR
Journal:  Nature       Date:  1953-10-03       Impact factor: 49.962

5.  Stable long-term mixed chimerism achieved in a canine model of allogeneic in utero hematopoietic cell transplantation.

Authors:  Jesse D Vrecenak; Erik G Pearson; Matthew T Santore; Carlyn A Todorow; Haiying Li; Antoneta Radu; Tricia Bhatti; William H Peranteau; Mark P Johnson; Alan W Flake
Journal:  Blood       Date:  2014-05-28       Impact factor: 22.113

6.  Immunophenotypic and ultrastructural heterogeneity of macrophage differentiation in bone marrow and fetal hematopoiesis of mouse in vitro and in vivo.

Authors:  Y Morioka; M Naito; T Sato; K Takahashi
Journal:  J Leukoc Biol       Date:  1994-05       Impact factor: 4.962

7.  Haploidentical in utero hematopoietic cell transplantation improves phenotype and can induce tolerance for postnatal same-donor transplants in the canine leukocyte adhesion deficiency model.

Authors:  William H Peranteau; Todd E Heaton; Yu-Chen Gu; Susan W Volk; Thomas R Bauer; Keith Alcorn; Laura M Tuschong; Mark P Johnson; Dennis D Hickstein; Alan W Flake
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

Review 8.  Immunological considerations in in utero hematopoetic stem cell transplantation (IUHCT).

Authors:  Andrea I Loewendorf; Marie Csete; Alan Flake
Journal:  Front Pharmacol       Date:  2015-01-06       Impact factor: 5.810

Review 9.  How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?

Authors:  Ying-Jun Chang; Leo Luznik; Ephraim J Fuchs; Xiao-Jun Huang
Journal:  J Hematol Oncol       Date:  2016-04-12       Impact factor: 17.388

Review 10.  Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Sarah Morin-Zorman; Pascale Loiseau; Jean-Luc Taupin; Sophie Caillat-Zucman
Journal:  Front Immunol       Date:  2016-08-12       Impact factor: 7.561

View more
  4 in total

1.  Prenatal Gene Therapy for Metabolic Disorders.

Authors:  Barbara Coons; William H Peranteau
Journal:  Clin Obstet Gynecol       Date:  2021-12-01       Impact factor: 1.966

2.  Regulatory T cells promote alloengraftment in a model of late-gestation in utero hematopoietic cell transplantation.

Authors:  John S Riley; Lauren E McClain; John D Stratigis; Barbara E Coons; Nicholas J Ahn; Haiying Li; Stavros P Loukogeorgakis; Camila G Fachin; Andre I B S Dias; Alan W Flake; William H Peranteau
Journal:  Blood Adv       Date:  2020-03-24

Review 3.  The Future of In Utero Gene Therapy.

Authors:  William H Peranteau; Alan W Flake
Journal:  Mol Diagn Ther       Date:  2020-04       Impact factor: 4.476

Review 4.  Experimental and clinical progress of in utero hematopoietic cell transplantation therapy for congenital disorders.

Authors:  Chunyu Shi; Lu Pan; Zheng Hu
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.